B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Publication ID:

LMP0816001

Publication Date:

August 1, 2016

Pages:

Publisher:

La Merie Publishing

Countries:

Global [1]

USD 570.00

Pharma & Healthcare [2]

Healthcare [3]

Description:

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target for enhanced immunotherapeutic strategies. This report describes and analyzes the

Scientific rationale for BCMA-targeted therapies;
Preclinical proof-of-concept of BCMA blockade;
Clinical experience with BCMA-targeted therapies;
The competitive landscape of BCMA-targeted treatment modalities;
Profiles of anti-BCMA CAR T-cells, antibody-drug conjugate and T-cell redirecting bispecific antibodies:
Profiles of companies involved in develompent of anti-BCMA therapy candidates.

Especially activity-enhanced antibodies and cells such as antibody-drug conjugates (ADCs) and T-cell redirecting bispecific antibodies as well as chimeric antigen receptor (CAR) T-cells, respectively, will benefit from the high target selectivity of BCMA to avoid on-target, off-tumor toxicity. As a consequence, novel cellular and humoral BCMA-targeted treatment modalities have emerged and resulting product candidates entered first-in-human clinical evaluation. Further development candidates are undergoing IND-enabling studies.

听

Table Of Contents:

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Table of Contents

1听听听听听听听听听 Target Background

2听听听听听听听听听 Target Antigen Expression Profile

3听听听听听听听听听 Preclinical Proof-of-Concept

4听听听听听听听听听 Clinical Indications & Treatment Options

5听听听听听听听听听 Clinical Experience with BCMA-Targeted Treatment Modalities

6听听听听听听听听听 Treatment Modalities & Competitive Landscape

7听听听听听听听听听 Drug & Cell Therapy Candidate Profiles
7.1听听听听听听 CAR T-Cells
7.2听听听听听听 Antibody-Drug Conjugate (ADC)
7.3听听听听听听 T-Cell Redirecting Antibodies

8听听听听听听听听听 Company Profiles

9听听听听听听听听听 References

听

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

麻豆原创